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Background: Anaemia is a common complication of infection with the human immunodeficiency virus (HIV) and
may have various causes. The aim of this study was to determine the prevalence and related factors of anemia in
HAART-naive HIV positive Patients.
Methods: A retrospective study was conducted on HAART naive HIV positive patients at the Gondar University
Hospital between September 2011 and August 2012. Socio-demographic and immunohematological (hemoglobin
and CD4+ T cells) data were collected carefully from the existing ART logbook and patient follow up cards.
Anaemia was defined according to the WHO criteria.
Results: The overall prevalence of anaemia was 138 (35%). Female HAART naive HIV positive patients had
significantly (P < 0.05) higher prevalence of anaemia than males (62% Vs 38%). The prevalence of anaemia at
different CD4 level was; 6 (4%) with CD4 count greater than 500 cells/μL, 18 (13%) with a CD4 count of 350–500
cells/μL, 37 (27%) with a CD4 count of 200–349 cells/μL, 44 (32%) with a CD4 count of 100–199 cells/μL, 14 (10%)
with a CD4 count of 50–99 and 19 (14%) with CD4 count of less than 50 cells/μL.
Conclusions: Our findings showed that one-third of HAART naïve HIV positive patients were anaemic and the
increase in prevalence of anaemia with decreased CD4 cell count was statistically significant. Therefore, early
diagnosis and treatment of anaemia in these patients are essential.
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Human immunodeficiency virus (HIV) infection is fre-
quently associated with hematologic abnormalities such as
anaemia. This association may have many causes [1,2]. A
systematic review of these abnormalities has shown that the
prevalence of anaemia in HIV positive patients ranges from
20-80% and is associated with faster disease progression
and mortality [3]. This makes it more common than
thrombocytopenia or leucopenia in patients with AIDS [4].
In established HIV infection, lower haemoglobin levels have
been shown to correlate with decreasing CD4+ cell counts
[5] and many studies have found an association between
anaemia during established infection and a faster progres-
sion to AIDS and death [6,7]. Therefore, interventions to* Correspondence: get29f@gmail.com
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distribution, and reproduction in any mediumprevent anaemia may lead to improved health and survival
potential of HIV-infected persons [8].
Anaemia has been reported to influence the natural his-
tory of HIV disease by increasing the rate of disease pro-
gression and mortality in both developed and developing
countries [1]. Mocroft et al. have demonstrated that severe
anaemia is linked with faster rate of HIV disease progres-
sion. They have also shown that anaemia is a strong pre-
dictor of death [9]. The consequences of untreated anemia
may lead to multisystem disabling symptoms and fatigue,
exhaustion, increased risk of HIV dementia, poor quality of
life and possibly even exacerbates poverty in communities
with a high HIV prevalence [10]. On the other hand, sur-
vival time in HIV-infected persons may be enhanced after
recovery from anemia [11].Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Socio-demographic characteristics of HAART
naive HIV positive patients at Gondar University
Hospital, Northwest Ethiopia, 2012
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mortality in HIV infected patients from low haemoglobin
levels even after adjusting for CD4 cell count and viral load
[3,7]. The etiology of anaemia in HIV infection is multifac-
torial and typically the anaemia may result from low pro-
duction of red blood cells, increased RBC destruction, or
ineffective RBC production [12] and frequently the labora-
tory features are compatible with anaemia of chronic
disease with a low reticulocyte count, normocytic and
normochromic red blood cells with normal iron stores and
cytokine mediated poor erythropoietin response [13,14].
Other mechanisms for HIV-associated anemia, al-
though uncommon, include vitamin B12 deficiency and
the autoimmune destruction of erythrocytes [15]. Direct
infection of marrow precursor cells [16] has been hy-
pothesized, but not proven. However, studies from de-
veloped countries suggest that the use of highly active
antiretroviral therapy (HAART) is associated with an in-
crease in haemoglobin concentrations and a decrease in
the prevalence of anaemia. Amelioration of HIV-related
anaemia with HAART has several benefits including im-
provements in functional status, energy levels and fa-
tigue and overall improvement in quality of life [16].
However, sufficient treatment of anaemia is not always
considered in developing countries. This is because most
notice is given to HIV infection and the frequent compli-
cations such as opportunistic infections [17]. Moreover,
there is wide variation in the prevalence of anaemia
among HIV/AIDS patients in different studies all over the
world and paucity information on the prevalence of an-
aemia among HIV patients in Ethiopia. This study there-
fore seeks to evaluate the prevalence of anaemia and the
related factors among HAART-naïve HIV positive patients
at different age groups, gender and CD4 levels.
Methods
A retrospective study of HAART naive HIV positive pa-
tients was conducted at Gondar University Hospital,
Northwest Ethiopia, between September 2011 and August
2012. Our study participants were adult (18 years or
above) HAART naive HIV positive individuals. HIV posi-
tive patients who were on antiretroviral therapy and preg-
nant women were excluded. Pre-ART HIV patients who
were on medication such as antibiotics, vitamin supple-
ments and tuberculosis treatments were also excluded
from the study.
Participant’s socio-demographic variables, history of
prophylaxis taken and hematological (hemoglobin) and im-
munological (CD4+ T cells) values were carefully extracted
from ART log book and patients follow up cards. Absolute
counts of CD4 lymphocytes were assayed using the BD
FACSCOUNT system (Becton Dickenson and Company,
California, USA). Haematological parameters such as
haemoglobin (Hb) were determined using the automatedblood analyzer Cell-Dyn 1800 (Abott Laboratories Diag-
nostics Division, USA).
Anaemia was defined according to the WHO criteria
[18]. For males, anaemia was defined as haemoglobin con-
centration (Hb) less than 13 g/dl, while for females; the
value is less than 12 g/dl. Mild anaemia was defined as a
haemoglobin level of 8-13 g/dl for men and 8-12 g/dl for
women. Severe anaemia was defined as a haemoglobin
level of less than 8 g/dl for both males and females.
Data were entered and analyzed by using SPSS version
16. Descriptive statistics (minimum, maximum, mean and
standard deviation) were determined for continuous vari-
ables in the course of analysis. Proportions and percent-
ages were calculated for categorical variables. For all
statistical comparisons of the groups, the Pearson Chi-
square test was used and P-value < 0.05 was considered as
statistically significant.
Ethical clearance was obtained from the Institutional
Ethical Review Board of University of Gondar. Permis-
sion for the conduct of the study was also obtained from
the University Hospital.
Results
A total of 420 HAART naive HIV positive patients’ chart
were reviewed but 20 of them were excluded from the
Table 2 Prevalence of anaemia among HAART naive HIV
positive patients at Gondar University Hospital,
Northwest Ethiopia, 2012
Degree of anemia Frequency Percentage (%)
Normal 262 65
Mild to moderate anemia 128 32
Severe anemia 10 3
Total 400 100
Table 4 Relationship between age groups and anaemia
among HAART naive HIV positive patients at Gondar
University Hospital, Northwest Ethiopia, 2012
Age group Frequency of anaemia Percentage (%) P – value
18-29 38 28 0.117
30-39 62 45
40-49 24 17
50 & above 14 10
Table 5 Relationship between varying degrees of CD4
count and anaemia among HAART naive HIV positive
patients at Gondar University Hospital, Northwest
Ethiopia, 2012
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nancy and those who were on medication (antibiotics and
vitamin supplements). The overall prevalence of anaemia
was 138 (35%) and majority of patients had mild to mod-
erate anemia. Mild to moderate anemia and severe anemia
occurred in 128 (32%) and 10 (3%) patients, respectively.
Female HAART naive HIV positive patients had signifi-
cantly higher prevalence of anaemia than males (62% Vs
38%) (P<0.05) (Table 1, 2 and 3).
Hemoglobin levels of the study participants were between
4.7 and 18 g/dL with the mean of 12.6 ± 2.0 g/dl. The mini-
mum CD4 count was 6 cells/μL, and the maximum was
1193 cells/μL. The mean CD4 count was 288±190.2 cells/
μL. In this study, majority of the anaemic cases 62 (45%)
were observed in the age group of 30–39 years. However,
the difference was not statistically significant (Table 4).
In this study, the prevalence of anaemia was showed stat-
istical significance (P<0.05) with CD4 T-cell count. We
found that 6 (4%) with CD4 count greater than 500 cells/
μL, 18 (13%) with a CD4 count of 350–500 cells/μL, 37
(27%) with a CD4 count of 200–349 cells/μL, 44 (32%) with
a CD4 count of 100–199 cells/μL, 14 (10%) with a CD4
count of 50–99 and 19 (14%), with CD4 count of less than
50 cells/μL (Table 5).
Discussion
Anaemia is frequently encountered aberration in HIV
patients [19] which may be clinically important. Multi-
factorial causes of anaemia may complicate its original
cause and/or its suitable treatment [20]. The prevalence of
anaemia in this study was 138 out of 400(35%) which is in
agreement with study of Mildvan et al., [21] and Levine
et al., [22]. However, low prevalence was reported by
Semba et al., who concluded that anaemia was in 28.1% of
HIV patients [23]. In addition Mata-Marin et al., [24] and
Akinsegun et al., [25] reported 20% and 24.2% prevalenceTable 3 Prevalence of anaemia by gender among HAART
naive HIV positive patients at Gondar University
Hospital, Northwest Ethiopia, 2012
Sex Frequency of anaemia Percentage (%) P – value
Male 53 38 0.013
Female 85 62of anemia among HAART naive HIV patients respectively,
which was lower than our study.
In this study, females had significantly higher prevalence
of anaemia than male patients 85 (62%) Vs 53 (38%)
(p<0.05), which is in agreement with findings of Owiredu
et al., [26] and Nadler et al., [27]. Moreover, mostly female
gender has been reported as a risk factor for anaemia
among HIV patients [27]. However, the finding in this
study was in contrast to the findings of a study conducted
in Nigeria [28].
In this study, as the immunity of a patient decreases, an-
aemia was more prevalent in patients rather than in HIV
positive patients who have relatively high CD4 count. For
example, the prevalence of anaemia was highest among
patients who had a CD4 lymphocyte count of 100–199
cells/μL and lowest among patients with a CD4 count >
500 cells/μL,. The increase in prevalence of anaemia with
decreased CD4 cell count was statistically significant (P <
0.05). Mostly, prevalence of anemia is higher among the
study participants who have low CD4 count. This finding
is consistent with the results of Levine et al., [22] and
Volberding et al., [29] who reported that more severe
levels of anemia are found among HIV positive patients
presenting with low CD4 counts.
The pathogenesis of HIV- related anemia is indistinct
and is possible to be multifactorial in nature [1,30,31]
Possible causes are bleeding (gastrointestinal malig-
nancy/severe infection), insufficient dietary intake (vita-
mins such as cobalamin and folate, iron, and general
malnutrition), haemolytic anaemia (i.e. malignancies, in-
fections, splenomegaly, immune dysfunction), changes inCD4 count Frequency of anaemia Percentage (%) P – value
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Suppression of the bone marrow in HIV-infected pa-
tients may be initiated in several ways. These include an
action of HIV itself (infection of the progenitor of the red
blood cell synthesis in late-stage disease), the use of anti-
retroviral drugs (primarily zidovudine), direct pathogenic
involvement of the bone marrow (malignant lymphoma,
atypical mycobacteriosis), prophylactic or therapeutic treat-
ment against opportunistic diseases or malignancies which
may suppress red blood cell production [23,32], however
since the HIV positive patients in this study were HAART-
naive and also devoid of coinfection with opportunistic dis-
eases, the anaemia could be associated with the low CD4
count, which concur with other studies [33,34].
To the best of our knowledge, this is the first study in
Ethiopia to determine prevalence of anaemia in HIV
HAART-naive infected patients. However, this study had
limitations such as the inability to estimate erythropoi-
etin levels and viral load. In addition, this study did not
include HIV infected patients who were on HAART.
Farther longitudinal studies should be conducted to de-
velop interventions aimed at reducing the prevalence of
anaemia in HIV infected patients. Moreover, studies on
serum iron, ferritin, and total iron binding capacity, folate,
cobalamin level and bone marrow could give more infor-
mation on the aetiology of anaemia in HIV infected indi-
viduals. These limitations notwithstanding, the results of
this study area true reflection of the circumstances of the
study participants and thus this study could serve as a ref-
erence for additional recommendations to improve care of
HIV infected persons and a step for further studies on the
pathophysiology of HIV associated anaemia in Ethiopia.
Conclusions
In conclusion, our findings showed that one-third of
HAART naive HIV positive patients in Northwest Ethiopia
are anaemic and the increase in prevalence of anemia with
decreased CD4 cell count was statistically significant. Sex
variation in the prevalence of anaemia was observed with
significant higher prevalence of anaemia observed among
females. Therefore, early diagnosis and treatment of an-
aemia is essential in these patients.
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